Health Care
Pharma, biotech, medical devices, insurers and providers.
| Company | Price | Today | 1 month | YTD |
|---|---|---|---|---|
| Amgen AMGN Biotechnology | 414.19 | ▼ 0.86% | +8.6% | +5.2% |
| Eli Lilly LLY Pharmaceuticals | 1,161.67 | ▼ 1.81% | +2.2% | +7.9% |
| Gilead Sciences GILD Biopharmaceuticals | 147.69 | ▼ 1.96% | +0.9% | +9.6% |
| Hims & Hers Health HIMS Digital health and telehealth | 29.53 | ▼ 3.43% | +2.5% | +43.0% |
| Intuitive Surgical ISRG Surgical Robotics and Medical Devices | 423.47 | ▼ 0.88% | +11.9% | +2.0% |
| Johnson & Johnson JNJ Pharmaceuticals and medical devices | 248.77 | ▼ 5.78% | −6.6% | −3.0% |
| Merck MRK Pharmaceuticals | 141.84 | ▼ 2.64% | −1.9% | −4.9% |
| Moderna MRNA Biotechnology | 218.08 | ▲ 2.41% | +48.5% | +31.1% |
| Novo Nordisk NVO Pharmaceuticals | 38.13 | ▼ 1.36% | −12.6% | −12.9% |
| UnitedHealth Group UNH Managed Health Care | 379.54 | ▼ 0.67% | −1.2% | +13.8% |
News across the sector
J&J Q3 2026 sales rise 5.9% to $25.4B; raises reported sales guidance
Johnson & Johnson reported third-quarter 2026 worldwide sales of $25.4 billion, up 5.9%, and adjusted EPS of $2.59, down 7.5%.
UnitedHealth Q3 2026 adjusted EPS $4.69 vs $2.92 a year ago; 2026 adjusted EPS floor raised to $20.50
UnitedHealth reported third-quarter 2026 revenue of $112.7 billion, slightly below $113.2 billion a year earlier, and adjusted EPS of $4.69 against $2.92.
J&J declares $1.34 quarterly dividend for fourth quarter 2026
The Board of Directors declared a cash dividend of $1.34 per share for the fourth quarter of 2026, announced alongside the third-quarter results.
Johnson & Johnson files 8-K: Results of Operations (Item 2.02)
Johnson & Johnson filed a Form 8-K with the SEC on Oct 13, 2026, 8:12 AM ET, reporting an event dated Oct 13, 2026.
Novo Nordisk: 6-K filed (report of foreign private issuer)
A Form 6-K (report of foreign private issuer) relating to Novo Nordisk was filed with the SEC on Oct 13, 2026, 6:15 AM ET.
UnitedHealth files 8-K: Results of Operations (Item 2.02)
UnitedHealth filed a Form 8-K with the SEC on Oct 13, 2026, 6:14 AM ET, reporting an event dated Oct 13, 2026.
Taltz plus Zepbound shows broader biomarker changes than Taltz alone in psoriasis
On October 9, 2026 Lilly reported exploratory biomarker data from the TOGETHER-PsO Phase 3b trial, presented at Fall Clinical Dermatology.
CMS releases 2027 Medicare Advantage Star Ratings; 71% of enrollees in 4-star-plus contracts
CMS published the 2027 Medicare Advantage and Part D Star Ratings on October 8, 2026.
Hims & Hers files 8-K: Director/Officer Change
Hims & Hers filed a Form 8-K with the SEC on Oct 7, 2026, 4:13 PM ET, reporting an event dated Oct 7, 2026.
Dutch court finds Keytruda SC infringes Halozyme patent, barring sales in eight European countries
A Dutch patent court found that Merck's subcutaneous Keytruda infringes Halozyme's EP 2,797,622 patent and rejected Merck's argument that the patent is invalid.
Novo Nordisk: 6-K filed (report of foreign private issuer)
A Form 6-K (report of foreign private issuer) relating to Novo Nordisk was filed with the SEC on Oct 6, 2026, 8:11 AM ET.
Lilly presents 21 dermatology presentations at Fall Clinical 2026
Lilly announced on October 5, 2026 that it would present 21 dermatology presentations at the Fall Clinical Dermatology Conference in Las Vegas, held October 8-11.
Novo Nordisk: 6-K filed (report of foreign private issuer)
A Form 6-K (report of foreign private issuer) relating to Novo Nordisk was filed with the SEC on Oct 2, 2026, 5:53 PM ET.
FDA approves Jaypirca as first-line treatment for untreated CLL/SLL
The FDA approved Jaypirca (pirtobrutinib) on October 2, 2026 as a first-line treatment for adults with previously untreated CLL or SLL who do not have a 17p deletion.
FDA extends review of denecimig haemophilia A BLA over manufacturing remediation
The FDA is still reviewing Novo's biologics license application for denecimig, a haemophilia A treatment, and has set no new decision date.